Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Immunochemotherapy and Partial Breast Irradiation in Early TNBC With Immune-cold Tumor Environment (KEY-MELT)

NCT07011823 is registered in ClinicalTrials.gov with Gangnam Severance Hospital as lead sponsor.

NCT NCT07011823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07011823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Immunochemotherapy and Partial Breast Irradiation in Early TNBC With Immune-cold Tumor Environment (KEY-MELT)
Lead sponsor
Gangnam Severance Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 16, 2025
Completion date
July 31, 2033
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast neoplasm